Sanuwave Announces Q3 FY2026 Financial Results

Sanuwave’s Q3 revenue and system sales fell sharply, swinging to a net loss.

What the company is saying

Sanuwave Health, Inc. reports a 24% year-over-year drop in Q3 2026 revenue to $8.6 million, with Ultramist® system sales plunging to 40 units from 155 in Q3 2025 and 82 in Q2 2026. The company highlights a 2% increase in Ultramist® applicator revenue to $6.9 million, maintaining gross margin at 77.3% versus 77.6% last year. CEO Morgan Frank attributes weak system sales to the CMS proposed rule, which led to customer exits among mobile wound care practitioners and a 'wait and see' market stance, compounded by a secondary market for used Ultramist® units. Sanuwave points to a 14% increase in HOPD rates for code 97610 and the removal of Q1 status as positive reimbursement changes. The narrative emphasizes ongoing traction in hospital settings and a focus on cost-saving users, while acknowledging the absence of last year’s $6.1 million non-cash gain and $5.0 million patent sale gain. The tone is factual, with management directly addressing regulatory and market headwinds and providing a detailed breakdown of financial drivers.

What the data suggests

The financials reveal a deteriorating trend: Q3 2026 revenue dropped to $8.6 million from $11.3 million a year earlier, and system sales fell by nearly 75%. Gross margin held steady at 77.3%, but operating results reversed from a $0.9 million profit to a $1.1 million loss. Net income of $9.7 million in Q3 2025 became a $1.4 million net loss, largely due to the absence of prior non-recurring gains and weaker operating performance. Adjusted EBITDA fell to $0.7 million from $3.2 million. The nine-month figures reinforce this pattern, with revenue down to $27.9 million from $30.7 million, gross margin percentage slipping, and net loss widening to $3.5 million from a $4.1 million profit. Cash and equivalents stood at $6.6 million after a $2.3 million outflow for sales tax settlements. The company’s balance sheet shows $32.5 million in assets, $29.7 million in liabilities, and $2.9 million in equity. Management’s explanation for the decline—regulatory uncertainty and customer exits—is consistent with the data, but claims of hospital traction are not quantified.

Analysis

The announcement is a factual quarterly financial report with detailed, transparent disclosure of revenue, gross margin, operating loss, net loss, adjusted EBITDA, cash, and balance sheet items. The tone is neutral and does not attempt to overstate performance; most claims are realised and supported by numerical data. The only forward-looking statements are generic (e.g., 'continues to see this as a core opportunity going forward'), with no exaggerated projections or unsupported optimism. The financial direction is clearly negative, with revenue, system sales, and profitability all declining year-over-year. There is no evidence of narrative inflation or overstatement; the company acknowledges the impact of regulatory changes and market headwinds. No large capital outlay is paired with long-dated, uncertain returns, and the execution distance for disclosed results is immediate.

Risk flags

• ●Sustained revenue and system sales declines signal ongoing demand and market share risk, especially as Q3 2026 system sales fell to 40 units from 155 a year earlier and 82 in the prior quarter, with no evidence of near-term recovery.
• ●Profitability has reversed sharply, with net loss of $1.4 million in Q3 2026 versus $9.7 million net income in Q3 2025, and adjusted EBITDA dropping from $3.2 million to $0.7 million, raising concerns about the company’s ability to return to sustained profitability.
• ●The company’s cash position, at $6.6 million after a $2.3 million outflow for sales tax settlements, limits financial flexibility if negative trends persist or further regulatory or market shocks occur.
• ●Regulatory uncertainty around CMS reimbursement and code 97610 continues to disrupt customer behavior and sales visibility, with management citing a 'wait and see' approach and customer exits as direct consequences.

Bottom line

Sanuwave’s Q3 2026 results show a steep drop in revenue and system sales, with the company moving from profit to loss as non-recurring gains from 2025 did not repeat and core demand weakened. Management’s explanation—regulatory uncertainty and customer exits—is credible and matches the data, but no quantified evidence supports claims of growing hospital traction or near-term turnaround. Cash reserves are modest relative to ongoing losses and recent outflows. The most important takeaway is the clear deterioration in both top-line and bottom-line performance, with regulatory and market headwinds still unresolved. Investors should focus on whether Sanuwave can stabilize system sales and demonstrate recurring revenue growth in future quarters, as ongoing losses and weak demand threaten both liquidity and long-term viability.

Announcement summary

(NASDAQ:SNWV) Sanuwave Health, Inc. reported financial results for the three months ended September 30, 2026. Revenue for Q3 2026 was $8.6 million, representing a decrease of 24% compared to $11.3 million in Q3 2025. The company sold 40 Ultramist® systems in Q3 2026, down from 155 in Q3 2025 and 82 in Q2 2026. Ultramist® applicator revenue increased by 2% to $6.9 million in Q3 2026, compared to $6.8 million in the same quarter last year. Gross margin as a percentage of revenue was 77.3% for Q3 2026, versus 77.6% for Q3 2025. Operating loss for the quarter was $1.1 million, compared to operating income of $0.9 million in Q3 2025. Net loss for Q3 2026 was $1.4 million, compared to net income of $9.7 million in Q3 2025. The year-over-year change was primarily due to a $6.1 million non-cash gain on the change in fair value of derivative liabilities and a one-time $5.0 million gain on the sale of patents in the prior-year period, neither of which recurred, and an operating loss of $1.1 million in the current period versus operating income of $0.9 million in the prior period, partially offset by a $1.5 million decrease in interest expense. Adjusted EBITDA for Q3 2026 was $0.7 million, compared to $3.2 million in Q3 2025. As of September 30, 2026, Sanuwave had $6.6 million in cash and cash equivalents, which was affected by approximately $2.3 million paid out under sales tax voluntary disclosure agreements during the quarter. CEO Morgan Frank stated that the CMS proposed rule, including the proposal to maintain skin substitute pricing at 2026 levels for 2027 and changes to the 97610 code, impacted customer behavior and system sales. The company noted a 14% increase in HOPD rates for 97610 and the removal of Q1 status from the code, allowing it to be billed alongside other procedures. Sanuwave continues to focus on hospital and cost-saving users as a core opportunity. For the nine months ended September 30, 2026, revenue was $27.9 million, down from $30.7 million in the same period of 2025. Gross margin for the nine months was $21.5 million (76.9%), compared to $24.0 million (78.2%) in 2025. Operating loss for the nine months was $2.5 million, compared to operating income of $2.9 million in 2025. Net loss for the nine months was $3.5 million, compared to net income of $4.1 million in 2025. Adjusted EBITDA for the nine months was $3.0 million, compared to $8.7 million in 2025. As of September 30, 2026, total assets were $32.5 million and total liabilities were $29.7 million. Stockholders’ equity was $2.9 million at quarter end. The company will hold a business update conference call on November 11, 2026 at 8:30 a.m. EST.

Disagree with this article?